The FDA has approved Tremfya® (guselkumab; Janssen) for the treatment of adult patients with active psoriatic arthritis. The Food and Drug Administration (FDA) has approved Tremfya® (guselkumab; ...

The recommended dosage for active PsA and moderate to severe plaque PsO in pediatric patients 6 years (≥40kg) is 100mg administered SC at week 0, 4, and then every 8 weeks thereafter. The Food and ...

Johnson & Johnson’s Tremfya is relatively new to the psoriatic arthritis race, where multiple players are vying for market share. Facing a new high-profile in-class rival from AbbVie, the New Jersey ...

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in health-related quality of life at week 100, ...

Johnson & Johnson is battling giants in the immunology field with its IL-23 inhibitor Tremfya. With other next-gen drugs already crowding the market, J&J now has the FDA's nod to take Tremfya into ...

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis By Lori Solomon HealthDay ReporterTHURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to ...

Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA) and also inhibits structural joint damage associated with the condition.

SPRING HOUSE, Pa., June 2, 2021 /PRNewswire/ — Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA (R) (guselkumab), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has approved guselkumab, an interleukin-23 ...